Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK2126458 + RXDX-105 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK2126458 | GSK458|Omipalisib | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | Omipalisib (GSK2126458) is a dual pan-PI3K and mTOR inhibitor, which blocks PI3K/AKT signaling to prevent cell proliferation (PMID: 24900173, PMID: 32382996). | |
RXDX-105 | AC013773|CEP-32496|Agerafenib | ABL Inhibitor (pan) 9 ABL1 Inhibitor 8 BCR-ABL Inhibitor 32 BRAF Inhibitor 25 CRAF Inhibitor 12 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 RET Inhibitor 53 VEGFR2 Inhibitor 37 | Agerafenib (RXDX-105) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199, PMID: 31695841). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - RET | lung adenocarcinoma | predicted - sensitive | GSK2126458 + RXDX-105 | Preclinical - Patient cell culture | Actionable | In a preclinical study, the addition of Omipalisib (GSK2126458) resulted in increased sensitivity to Agerafenib (RXDX-105) treatment in a patient-derived lung adenocarcinoma cell line harboring EML4-RET in culture (PMID: 33795352). | 33795352 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|